Is ARTV or ATYR more undervalued in 2026?

CirclFi compares Artiva Biotherapeutics, Inc. (ARTV) and aTyr Pharma, Inc. (ATYR) using 13 institutional-grade valuation models. ARTV has a Quality of Company score of 4.9/10 while ATYR scores 4.9/10.

Which is a better buy — ARTV or ATYR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ARTV and ATYR valuations compare?

ARTV at $7.93 and ATYR at $0.54 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ARTV vs ATYR Valuation Comparison 2026 — Intrinsic Value Analysis

ARTV

Biological Products, (No Diagnostic Substances)

Artiva Biotherapeutics, Inc.

Quality

4.9

out of 10

Value Trap

SAFE

Price

$7.93

Last close

Models

9/13

Active

ATYR

Biological Products, (No Diagnostic Substances)

aTyr Pharma, Inc.

Quality

4.9

out of 10

Value Trap

WARN

Price

$0.54

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	ARTV Fair Value	ARTV Upside	ATYR Fair Value	ATYR Upside
Bayesian DCF	Intrinsic	$2.27	-71.4%	$0.15	-72.4%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.32	-83.3%	$0.72	+32.9%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ARTV vs ATYR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ARTV vs ATYR — Which Stock Is More Undervalued?

ARTV scores higher with a 4.9/10 quality rating vs ATYR's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Artiva Biotherapeutics, Inc. (ARTV) and aTyr Pharma, Inc. (ATYR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ARTV currently trades at $7.93 with a QOC of 4.9/10, while ATYR trades at $0.54 with a QOC of 4.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).